KMT2A and acute myeloid leukemia: In particular, we sought to investigate whether DOT1L inhibition with Pinometostat could sensitize AML cells, irrespectively of MLL fusions, to Sorafenib, a multi-kinase inhibitor with activity against FLT3, members of the RAF/MEK/ERK signaling pathway, VEGFR2, PDGFR, and KIT [24].